Eli Lilly: Insulin Product’s Entire Ecosystem Should Factor Into Switches

By Beth Wang / May 14, 2019 at 12:12 PM
Biologic maker Eli Lilly is calling for FDA to consider an insulin product’s entire ecosystem -- from delivery devices to monitors to mobile apps in addition to the insulin itself -- when deciding whether products are interchangeable, an unexpected stance that an FDA official and the generic drug and biosimilars lobby suggested could delay the availability of interchangeable insulin. After an Eli Lilly representative proposed the ecosystem approach at an FDA public meeting on insulin biosimilars Monday (May 13), the...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.